Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Life Sciences & Biomedicine (13)
- Science & Technology (13)
- Oncology (9)
- Cell Biology (3)
- General & Internal (3)
-
- METASTATIC LIPOSARCOMA (3)
- SOFT-TISSUE SARCOMA (3)
- Sarcoma (3)
- Biochemistry & Molecular Biology (2)
- CANCER (2)
- CHEMOTHERAPY (2)
- DOUBLE-BLIND (2)
- EFFICACY (2)
- Hematology (2)
- IONIZING-RADIATION (2)
- Medicine (2)
- Myeloid (2)
- OPEN-LABEL (2)
- PHASE-II (2)
- Research & Experimental (2)
- Research & Experimental Medicine (2)
- SAFETY (2)
- SURVIVAL (2)
- THERAPY (2)
- Trabectedin (2)
- *Gene Expression Regulation (1)
- 1ST-LINE TREATMENT (1)
- 5-Fluorouracil;; cancer;; chemotherapy;; colorectal;; cure;; metastatic (1)
- ACUTE LYMPHOBLASTIC-LEUKEMIA (1)
- ACUTE MYELOID-LEUKEMIA;; SOUTHWEST-ONCOLOGY-GROUP;; COMPLETE REMISSION;; AGE;; CYTARABINEDAUNORUBICIN;; DAUNORUBICIN;; CYTOGENETICS;; INDUCTION;; CHEMOTHERAPY;; FORMULATION;; Hematology (1)
Articles 1 - 30 of 95
Full-Text Articles in Medicine and Health Sciences
Combination Of Dasatinib With Chemotherapy In Previously Untreated Core Binding Factor Acute Myeloid Leukemia: Calgb 10801, G. Marcucci, S. Geyer, K. Laumann, W. Zhao, D. Bucci, G. L. Uy, W. Blum, A. K. Eisfeld, J. E. Kolitz, R. A. Larson, +7 Additional Authors
Combination Of Dasatinib With Chemotherapy In Previously Untreated Core Binding Factor Acute Myeloid Leukemia: Calgb 10801, G. Marcucci, S. Geyer, K. Laumann, W. Zhao, D. Bucci, G. L. Uy, W. Blum, A. K. Eisfeld, J. E. Kolitz, R. A. Larson, +7 Additional Authors
Journal Articles
© 2020 by The American Society of Hematology. Acutemyeloid leukemia (AML)witheither t(8;21)(q22;q22)or inv(16)(p13q22)/t(16;16)(p13;q22) is referred to as core binding factor (CBF) AML. Although categorized as favorable risk, long-term survival for these patients is only ∼50% to 60%. Mutated (mut) or overexpressed KIT, a gene encoding a receptor tyrosine kinase, has been found almost exclusively in CBF AML and may increase the risk of disease relapse. We tested the safety and clinical activity of dasatinib, a multi-kinase inhibitor, in combination with chemotherapy. Sixty-one adult patients with AML and CBF fusion transcripts (RUNX1/RUNX1T1 or CBFB/MYH11) were enrolled on Cancer and Leukemia Group …
Multiplex Accurate Sensitive Quantitation (Masq) With Application To Minimal Residual Disease In Acute Myeloid Leukemia, A. B. Moffitt, M. S. Spector, P. Andrews, J. Kendall, J. Alexander, A. Stepansky, J. Kolitz, N. Chiorazzi, S. L. Allen, Z. Wang, +4 Additional Authors
Multiplex Accurate Sensitive Quantitation (Masq) With Application To Minimal Residual Disease In Acute Myeloid Leukemia, A. B. Moffitt, M. S. Spector, P. Andrews, J. Kendall, J. Alexander, A. Stepansky, J. Kolitz, N. Chiorazzi, S. L. Allen, Z. Wang, +4 Additional Authors
Journal Articles
No abstract provided.
Mutations Associated With A 17-Gene Leukemia Stem Cell Score And The Score’S Prognostic Relevance In The Context Of The European Leukemianet Classification Of Acute Myeloid Leukemia, M. Bill, D. Nicolet, J. Kohlschmidt, C. J. Walker, K. Mrózek, A. K. Eisfeld, D. Papaioannou, X. Rong-Mullins, J. E. Kolitz, C. D. Bloomfield, +8 Additional Authors
Mutations Associated With A 17-Gene Leukemia Stem Cell Score And The Score’S Prognostic Relevance In The Context Of The European Leukemianet Classification Of Acute Myeloid Leukemia, M. Bill, D. Nicolet, J. Kohlschmidt, C. J. Walker, K. Mrózek, A. K. Eisfeld, D. Papaioannou, X. Rong-Mullins, J. E. Kolitz, C. D. Bloomfield, +8 Additional Authors
Journal Articles
© 2020 Ferrata Storti Foundation. Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understanding of the mutational patterns and the prognostic impact of molecular markers associated with stemness could lead to better clinical management and improve patients’ outcomes. We applied a previously described 17-gene expression score comprising genes differently expressed between LSC and leukemic bulk blasts, for 934 adult patients with de novo AML, and studied associations of the 17-gene LSC …
Pretreatment Nutritional Status And Response To Checkpoint Inhibitors In Lung Cancer., C. Lee, C. E. Devoe, X. Zhu, J. S. Fishbein, N. Seetharamu
Pretreatment Nutritional Status And Response To Checkpoint Inhibitors In Lung Cancer., C. Lee, C. E. Devoe, X. Zhu, J. S. Fishbein, N. Seetharamu
Journal Articles
Background:Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data suggests that nutritional status may play a role in antitumor immunity. Materials & methods:This retrospective study of 106 non-small-cell lung cancer patients who started checkpoint inhibitors between 2014 and 2017 at our institution assessed relationship of nutritional parameters to overall survival (OS) and progression-free survival. Results:Mean age was 68.7 ± 9.2 years and 59.4% patients were male. On multivariate analysis for OS, hypoalbuminemia and significant weight loss were prognostic at p-values of 0.0005 and 0.0052, respectively. We noted a parabolic association between age and OS (p = 0.026, 0.0025). …
A Case Of Vancomycin-Induced Immune Thrombocytopenia., K. N. Macdougall, S. Parylo, A. Sokoloff
A Case Of Vancomycin-Induced Immune Thrombocytopenia., K. N. Macdougall, S. Parylo, A. Sokoloff
Journal Articles
Vancomycin-induced immune thrombocytopenia (ITP) is a rare, potentially life-threatening complication from an antibiotic frequently used in medical practice. We report a case of an 81-year-old male with recent removal of an infected right knee prosthesis and insertion of an articulating antibiotic spacer, presenting from rehabilitation for severe thrombocytopenia (1 X 103/µL). The patient's thrombocytopenia was initially falsely attributed to rifampin-induced ITP, a much more common cause of drug-induced thrombocytopenia. Only later, after a second precipitous drop in platelet count, vancomycin was correctly identified as the culprit. The patient's serum was tested for drug-dependent platelet antibodies with and without vancomycin. A …
Tumor-Associated Macrophages And Macrophage-Related Immune Checkpoint Expression In Sarcomas, A. R. Dancsok, D. Gao, A. F. Lee, S. E. Steigen, J. Blay, D. M. Thomas, R. G. Maki, T. O. Nielsen, E. G. Demicco
Tumor-Associated Macrophages And Macrophage-Related Immune Checkpoint Expression In Sarcomas, A. R. Dancsok, D. Gao, A. F. Lee, S. E. Steigen, J. Blay, D. M. Thomas, R. G. Maki, T. O. Nielsen, E. G. Demicco
Journal Articles
No abstract provided.
Covid-19 And Cancer Patients., R Patel, J Park, A Shah, Mw Saif
Covid-19 And Cancer Patients., R Patel, J Park, A Shah, Mw Saif
Journal Articles
No abstract provided.
Telemedicine For Cancer Patients During Covid-19 Pandemic: Between Threats And Opportunities, R Elkaddoum, Fg Haddad, R Eid, Hr Kourie
Telemedicine For Cancer Patients During Covid-19 Pandemic: Between Threats And Opportunities, R Elkaddoum, Fg Haddad, R Eid, Hr Kourie
Journal Articles
No abstract provided.
Covid-19 Clinical Research., J. Chi, D. Chitty, M. Lee, N. Hakim, S. Lakhani, L. Rajdev, X. Zhu, M. W. Saif
Covid-19 Clinical Research., J. Chi, D. Chitty, M. Lee, N. Hakim, S. Lakhani, L. Rajdev, X. Zhu, M. W. Saif
Journal Articles
Introduction:While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency. Areas covered:We searched the NCI website and Medline and summarize various national and international clinical trials and summarize few of the pivotal ones in this paper, including those specific to oncology population. Two …
Lessons Learnt From Covid-19: How Can We Prepare For Another Pandemic?, M. I. Ehrlich, M. W. Saif
Lessons Learnt From Covid-19: How Can We Prepare For Another Pandemic?, M. I. Ehrlich, M. W. Saif
Journal Articles
No abstract provided.
Management Of Pancreatic Cancer During Covid-19 Pandemic: To Treat Or Not To Treat?, R. Patel, M. W. Saif
Management Of Pancreatic Cancer During Covid-19 Pandemic: To Treat Or Not To Treat?, R. Patel, M. W. Saif
Journal Articles
Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from …
Sarcoma European And Latin American Network (Selnet) Recommendations On Prioritization In Sarcoma Care During The Covid-19 Pandemic, J. Martin-Broto, N. Hindi, S. Aguiar, R. Badilla-Gonzalez, V. Castro-Oliden, M. Chacon, R. Correa-Generoso, E. De Alava, R. Maki, J. Blay, +25 Additional Authors
Sarcoma European And Latin American Network (Selnet) Recommendations On Prioritization In Sarcoma Care During The Covid-19 Pandemic, J. Martin-Broto, N. Hindi, S. Aguiar, R. Badilla-Gonzalez, V. Castro-Oliden, M. Chacon, R. Correa-Generoso, E. De Alava, R. Maki, J. Blay, +25 Additional Authors
Journal Articles
No abstract provided.
Optimizing Tissue Use: A Step-Wise Approach To Diagnosing Squamous Cell Lung Carcinoma On Small Biopsies, C. Olazagasti, I. Preeshagul, M. Aziz, N. Seetharamu
Optimizing Tissue Use: A Step-Wise Approach To Diagnosing Squamous Cell Lung Carcinoma On Small Biopsies, C. Olazagasti, I. Preeshagul, M. Aziz, N. Seetharamu
Journal Articles
© The Author(s) 2020. Background: Histologic subtyping of lung cancer has significant implications for treatment planning. Accurate diagnosis based on cytology/small biopsy specimens is challenging and frequently determined by morphology, as material is often not sufficient for immunohistochemical studies (IHC). We investigated the concordance between the rates of diagnosis from cytology/small biopsies compared with surgical specimens in patients with squamous cell lung cancer (SCC) and the utility of IHC for diagnostic precision in lung cancer subtyping. Methods: We conducted a 5-year retrospective analysis identifying cases of SCC diagnosed on cytology/small biopsies ± IHC and compared them with subsequent surgical specimens …
Ibrutinib Restores Immune Cell Numbers And Function In First-Line And Relapsed/Refractory Chronic Lymphocytic Leukemia, I. G. Solman, L. K. Blum, H. Y. Hoh, T. J. Kipps, J. A. Burger, J. C. Barrientos, S. O'Brien, S. P. Mulligan, N. E. Kay, A. Mongan, +4 Additional Authors
Ibrutinib Restores Immune Cell Numbers And Function In First-Line And Relapsed/Refractory Chronic Lymphocytic Leukemia, I. G. Solman, L. K. Blum, H. Y. Hoh, T. J. Kipps, J. A. Burger, J. C. Barrientos, S. O'Brien, S. P. Mulligan, N. E. Kay, A. Mongan, +4 Additional Authors
Journal Articles
© 2020 The Authors Ibrutinib positively modulates many T-cell subsets in chronic lymphocytic leukemia (CLL). To understand ibrutinib's effects on the broader landscape of immune cell populations, we comprehensively characterized changes in circulating counts of 21 immune blood cell subsets throughout the first year of treatment in patients with relapsed/refractory (R/R) CLL (n = 55, RESONATE) and previously untreated CLL (n = 50, RESONATE-2) compared with untreated age-matched healthy donors (n = 20). Ibrutinib normalized abnormal immune cell counts to levels similar to those of age-matched healthy donors. Ibrutinib significantly decreased pathologically high circulating B cells, regulatory T cells, effector/memory …
A Comprehensive Review Of Contemporary Literature For Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Non-Small Cell Lung Cancer And Their Toxicity, C. S. Lee, S. Sharma, E. Miao, C. Mensah, K. Sullivan, N. Seetharamu
A Comprehensive Review Of Contemporary Literature For Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Non-Small Cell Lung Cancer And Their Toxicity, C. S. Lee, S. Sharma, E. Miao, C. Mensah, K. Sullivan, N. Seetharamu
Journal Articles
© 2020 Lee et al. Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully …
A Randomized,Double-Blind,Placebo-Controlled, Phaseiistudy Of Regorafenib Versus Placebo In Advanced/Metastatic,Treatment-Refractoryliposarcoma: Results From Thesarc024study, R. F. Riedel, K. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. Chow, J. Wright, R. G. Maki, +10 Additional Authors
A Randomized,Double-Blind,Placebo-Controlled, Phaseiistudy Of Regorafenib Versus Placebo In Advanced/Metastatic,Treatment-Refractoryliposarcoma: Results From Thesarc024study, R. F. Riedel, K. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. Chow, J. Wright, R. G. Maki, +10 Additional Authors
Journal Articles
No abstract provided.
Evaluating Of Hpv-Dna Ish As An Adjunct To P16 Testing In Oropharyngeal Cancer, J. Chi, I. R. Preeshagul, S. Sheikh-Fayyaz, S. Teckie, N. Kohn, Y. Ziemba, A. Laser, D. Frank, M. Ghaly, D. Kamdar, D. Kraus, D. Paul, N. Seetharamu
Evaluating Of Hpv-Dna Ish As An Adjunct To P16 Testing In Oropharyngeal Cancer, J. Chi, I. R. Preeshagul, S. Sheikh-Fayyaz, S. Teckie, N. Kohn, Y. Ziemba, A. Laser, D. Frank, M. Ghaly, D. Kamdar, D. Kraus, D. Paul, N. Seetharamu
Journal Articles
© 2020 Jeffrey Chi. Aim: Current guidelines recommend p16 immunohistochemistry (IHC) for testing human papillomavirus (HPV) in oropharyngeal carcinoma (OPSCC). We evaluated the value of adding DNA in situ hybridization (ISH) to p16 IHC. Methods: Fifty patients with OPSCC were analyzed. Concordance between HPV-DNA ISH and p16 IHC was measured by Gwet's agreement coefficient. Results: p16 IHC was positive in 35/48 (72.9%), negative in 8/48 (16.7%) patients. Wide spectrum DNA-ISH was positive in 9/23 (39%) and negative in 14/23 (60.9%) patients. High-risk 16/18 (HR) HPV DNA-ISH was positive in 11/23 (47.8%) and negative in 12 (52.2%) patients. The agreement between …
Rapid Donor Identification Improves Survival In High-Risk First-Remission Patients With Acute Myeloid Leukemia, J. M. Pagel, M. Othus, G. Garcia-Manero, M. Fang, J. P. Radich, D. A. Rizzieri, G. Marcucci, S. A. Strickland, R. L. Bayer, F. R. Appelbaum, +10 Additional Authors
Rapid Donor Identification Improves Survival In High-Risk First-Remission Patients With Acute Myeloid Leukemia, J. M. Pagel, M. Othus, G. Garcia-Manero, M. Fang, J. P. Radich, D. A. Rizzieri, G. Marcucci, S. A. Strickland, R. L. Bayer, F. R. Appelbaum, +10 Additional Authors
Journal Articles
PURPOSE: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT. METHODS: We used a prospective organized approach to rapidly identify donors to improve the allogeneic HCT rate in adults with high-risk acute myeloid leukemia in CR1. Newly diagnosed patients had cytogenetics obtained at enrollment, and those with high-risk cytogenetics underwent expedited HLA typing and were encouraged to be referred for consultation with a transplantation team with the goal of …
A Framework For Advancing Our Understanding Of Cancer-Associated Fibroblasts, E. Sahai, I. Astsaturov, E. Cukierman, D. G. Denardo, M. Egeblad, R. M. Evans, D. Fearon, R. G. Maki, D. C. Ramirez, Z. Werb, +10 Additional Authors
A Framework For Advancing Our Understanding Of Cancer-Associated Fibroblasts, E. Sahai, I. Astsaturov, E. Cukierman, D. G. Denardo, M. Egeblad, R. M. Evans, D. Fearon, R. G. Maki, D. C. Ramirez, Z. Werb, +10 Additional Authors
Journal Articles
No abstract provided.
Clinical And Functional Significance Of Circular Rnas In Cytogenetically Normal Aml, D. Papaioannou, S. Volinia, D. Nicolet, M. Swierniak, A. Petri, K. Mrozek, M. Bill, F. Pepe, J. E. Kolitz, R. Garzon, +10 Additional Authors
Clinical And Functional Significance Of Circular Rnas In Cytogenetically Normal Aml, D. Papaioannou, S. Volinia, D. Nicolet, M. Swierniak, A. Petri, K. Mrozek, M. Bill, F. Pepe, J. E. Kolitz, R. Garzon, +10 Additional Authors
Journal Articles
No abstract provided.
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Journal Articles
No abstract provided.
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
Journal Articles
No abstract provided.
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Journal Articles
No abstract provided.
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Journal Articles
No abstract provided.
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
Journal Articles
No abstract provided.
Phase Ii Randomised Discontinuation Trial Of Brivanib In Patients With Advanced Solid Tumours, R. L. Jones, M. J. Ratain, P. J. O'Dwyer, L. L. Siu, J. Jassem, J. Medioni, M. Dejonge, C. Rudin, R. Maki, G. Schwartz, +20 Additional Authors
Phase Ii Randomised Discontinuation Trial Of Brivanib In Patients With Advanced Solid Tumours, R. L. Jones, M. J. Ratain, P. J. O'Dwyer, L. L. Siu, J. Jassem, J. Medioni, M. Dejonge, C. Rudin, R. Maki, G. Schwartz, +20 Additional Authors
Journal Articles
© 2019 The Author(s) Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]). Patients and methods: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response to …
Complex Karyotype In De Novo Acute Myeloid Leukemia: Typical And Atypical Subtypes Differ Molecularly And Clinically, K. Mrózek, A. K. Eisfeld, J. Kohlschmidt, A. J. Carroll, C. J. Walker, D. Nicolet, J. S. Blachly, M. Bill, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors
Complex Karyotype In De Novo Acute Myeloid Leukemia: Typical And Atypical Subtypes Differ Molecularly And Clinically, K. Mrózek, A. K. Eisfeld, J. Kohlschmidt, A. J. Carroll, C. J. Walker, D. Nicolet, J. S. Blachly, M. Bill, J. E. Kolitz, C. D. Bloomfield, +7 Additional Authors
Journal Articles
© 2019, Springer Nature Limited. Complex karyotype (CK) with ≥ 3 abnormalities is detected in 10–12% of patients with acute myeloid leukemia (AML) and associated with poor prognosis. The most common unbalanced abnormalities found in CK result in loss of material from the 5q, 7q, and/or 17p chromosome arms. The presence of 5q, 7q, and/or 17p abnormalities denotes typical CK and their absence denotes atypical CK. Since molecular features of CK-AML are not well characterized, we investigated mutational status of 81 leukemia/cancer-associated genes in 160 clinically well-characterized patients. They included 136 patients with ≥ 3 exclusively unbalanced chromosome abnormalities, 96 …
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Journal Articles
No abstract provided.
Radiation Recall Pneumonitis In The Setting Of Immunotherapy And Radiation: A Focused Review, K. Mcgovern, M. Ghaly, M. Esposito, K. Barnaby, N. Seetharamu
Radiation Recall Pneumonitis In The Setting Of Immunotherapy And Radiation: A Focused Review, K. Mcgovern, M. Ghaly, M. Esposito, K. Barnaby, N. Seetharamu
Journal Articles
© 2019 Nagashree Seetharamu. Radiation recall pneumonitis (RRP) is an entity described as pneumonitis localized to a previously irradiated field after exposure to a systemic agent. It has previously been described in the literature in the context of chemotherapeutic agents as well as certain biologics. With immunotherapy taking a more prominent role in the treatment of several different malignancies and its own baseline risk of pneumonitis, it is important to explore the likelihood of RRP, specifically in those patients who have been previously treated with radiation therapy. The current literature regarding RRP with checkpoint inhibitors is reviewed in this article. …
Delivering Challenging News: An Illness-Trajectory Communication Curriculum For Multispecialty Oncology Residents And Fellows, D. Cannone, M. Atlas, A. Fornari, M. L. Barilla-Labarca, M. Hoffman
Delivering Challenging News: An Illness-Trajectory Communication Curriculum For Multispecialty Oncology Residents And Fellows, D. Cannone, M. Atlas, A. Fornari, M. L. Barilla-Labarca, M. Hoffman
Journal Articles
Introduction: Published curricula to teach communication skills for postgraduate fellows in oncology are few in number despite the fact that oncologists conduct many difficult discussions with their patients and their families. Such discussions may include disclosing initial diagnosis or relapse of a patient's cancer or relaying a poor prognosis or change to palliative care. Methods: An eight-module course on communication in oncology practice was delivered over 2 months for palliative and oncology fellows and radiation oncology residents. Learners were given a precourse survey in which they were asked to rate their proficiency in various communication tasks. Each learner then participated …